Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Don M Benson

Showing results (51-60 of 110) with videos related to

Pageof 11
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|October 6, 2009
CD94 defines phenotypically and functionally distinct mouse NK cell subsetsJianhua Yu, Min Wei, Hsiaoyin Mao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2014
A phase I trial of single-agent reolysin in patients with relapsed multiple myelomaDouglas W Sborov, Gerard J Nuovo, Andrew Stiff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2012
Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myelomaAndrzej J Jakubowiak, Don M Benson, William Bensinger, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 14, 2019
Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-UpNidhi Sharma, David T Chen, Qiuhong Zhao, et al.
Leukemia & Lymphoma|August 29, 2014
Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplantGalena Salem, Amy S Ruppert, Patrick Elder, et al.
Nature Immunology|December 13, 2018
The IL-15-AKT-XBP1s signaling pathway contributes to effector functions and survival in human NK cellsYufeng Wang, Yibo Zhang, Ping Yi, et al.
Cancer Immunology Research|May 18, 2018
A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple MyelomaWing Keung Chan, Siwen Kang, Youssef Youssef, et al.
Proteomics|August 29, 2013
Characterization of multiple myeloma vesicles by label-free relative quantitationSean W Harshman, Alessandro Canella, Paul D Ciarlariello, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 25, 2019
T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple MyelomaFabienne Lucas, Michael Pennell, Ying Huang, et al.
Leukemia & Lymphoma|February 16, 2019
Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experienceFiliz Yucebay, Christina Matthews, Marcin Puto, et al.
Pageof 11

Showing results (51-60 of 110) with videos related to

Sort By:
Pageof 11
Journal of Immunology (Baltimore, Md. : 1950)|October 6, 2009
CD94 defines phenotypically and functionally distinct mouse NK cell subsetsJianhua Yu, Min Wei, Hsiaoyin Mao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2014
A phase I trial of single-agent reolysin in patients with relapsed multiple myelomaDouglas W Sborov, Gerard J Nuovo, Andrew Stiff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2012
Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myelomaAndrzej J Jakubowiak, Don M Benson, William Bensinger, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 14, 2019
Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-UpNidhi Sharma, David T Chen, Qiuhong Zhao, et al.
Leukemia & Lymphoma|August 29, 2014
Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplantGalena Salem, Amy S Ruppert, Patrick Elder, et al.
Nature Immunology|December 13, 2018
The IL-15-AKT-XBP1s signaling pathway contributes to effector functions and survival in human NK cellsYufeng Wang, Yibo Zhang, Ping Yi, et al.
Cancer Immunology Research|May 18, 2018
A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple MyelomaWing Keung Chan, Siwen Kang, Youssef Youssef, et al.
Proteomics|August 29, 2013
Characterization of multiple myeloma vesicles by label-free relative quantitationSean W Harshman, Alessandro Canella, Paul D Ciarlariello, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 25, 2019
T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple MyelomaFabienne Lucas, Michael Pennell, Ying Huang, et al.
Leukemia & Lymphoma|February 16, 2019
Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experienceFiliz Yucebay, Christina Matthews, Marcin Puto, et al.
Pageof 11